NEWS
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
Revelation Biosciences (NASDAQ: REVB) has completed enrollment and dosing of its first-in-human Phase 1 clinical study (RVL-HV02) for Gemini, conducted in Australia.
The study evaluated escalating doses of intravenously administered Gemini in 40 healthy individuals aged 18-55. The forthcoming top-line data will assess safety and tolerability, along with biomarkers to demonstrate immune response stimulation.
Positive data could support Gemini's future development for multiple indications, including reducing acute kidney injury and post-surgical infections.
Preclinical studies have shown promising results in reducing AKI severity and bacterial infections.
Revelation's CEO, James Rolke, highlighted the milestone's significance for addressing critical unmet needs.
The study evaluated escalating doses of intravenously administered Gemini in 40 healthy individuals aged 18-55. The forthcoming top-line data will assess safety and tolerability, along with biomarkers to demonstrate immune response stimulation.
Positive data could support Gemini's future development for multiple indications, including reducing acute kidney injury and post-surgical infections.
Preclinical studies have shown promising results in reducing AKI severity and bacterial infections.
Revelation's CEO, James Rolke, highlighted the milestone's significance for addressing critical unmet needs.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1258Followers
76Following
8842Visitors
Follow